CURRENT TRENDS IN THE TREATMENT OF OVERACTIVE BLADDER IN WOMEN


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The overactive bladder (OAB) is a symptom complex that is accompanied by urgency with and without urgency urinary incontinence, by more frequent daytime urination, and nocturia. Despite the fact that this condition poses no threat to life, OAB exerts a significant impact on quality of life. The total prevalence of OAB symptoms is 12-22%. Muscarinic antagonists (M-choline blockers), ß-adrenoblocker agonists, potassium channel modulators, and other drugs are now used to treat OAB. M-choline blockers are, in terms of evidence-based medicine, first-line agents (Level 1 evidence and Grade A recommendation) with a low side-effectprofile.

全文:

受限制的访问

作者简介

I. APOLIKHINA

I.M. Sechenov First Moscow State Medical University

Email: apolikhina@inbox.ru
Department of Obstetrics, Gynecology, Perinatology, and Reproductology

F. MAKHMEDZHANOVA

Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

S. MUSLIMOVA

Urology Research Institute, Russian Agency for Medical Technologies

参考

  1. Абдуллин И.И., Хазан П.Л., Козырев С.В. Внутрипузырные инъекции ботулинического токсина типа А при лучевом цистите // Эксперим. и клин. урол. — 2010. — № 1. — С. 85—86.
  2. Пушкарь Д.Ю., Щавелева О.Б. Гиперактивный мочевой пузырь: эпидемиология, диагностика, сравнительная оценка медикаментозной терапии // Фарматека. — 2004. — № 16 (93). — С. 26.
  3. Ромих В.В., Захарченко А.В., Коршунова Е.С. Использование ботулинического токсина типа А у пациентов с нейрогенными нарушениями мочеиспускания // Эксперим. и клин. урол. — 2010. — № 1. — С. 81—85.
  4. Abrams P., Cardozo L., Fall M. et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committe of ICS // Neurol. Urodyn. — 2002. — Vol. 21. — P. 167—178.
  5. Brunton S., Kuritzky L. Recent developments in the management of overactive bladder // Curr. Med. Res. Opin. — 2005. — Vol. 21. — P. 71—80.
  6. Chancellor M., Zinner N, Whitmore K. et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study // Clin. Ther. — 2008. — Vol. 30, № 10. — P. 1766—1781.
  7. Chapple C.R., Arano P., Bosch J. et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose — finding study // Br. J. Urol. Int. — 2004. — Vol. 93. — P. 71—77.
  8. Garely A.D., Kaufman J.M., Sand P.K. et al. Symptom bother and health-related quality of life outcomes following Solifenacin treatment for overactive bladder: the Vesicare Open-Label Trial (VOLT) // Clin. Ther. — 2006. — Vol. 28. — P. 1935—1946.
  9. Hall J.A., Nelson M.A., Meyer J.W et al. Cost and resource associated with the treatment overactive bladder using retrospective medical care claim data // Manag. Care Interface. — 2001. — Vol. 8. — P. 69—75.
  10. Hegde S.S. Muscarinic receptors in the bladder: from basic research to therapeutics // Br. J. Pharmacol. — 2006. — Vol. 147. — P. 580—587.
  11. Liu Hsin-Tzu, Chancellor Michael B., Kuo Hann-Chorng. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection // Eur. urol. — 2009. — Vol. 56. — P. 700—707.
  12. Liu Hsin-Tzu, Chancellor Michael B., Kuo Hann-Chorng. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder // Br. J. Urol. Int. — 2009. — Vol. 103, № 12. — Р. 1668—1672.
  13. Irwin D., Milsom I., Kopp Z. et al. Overactive bladder symptom prevalence and health-care-seeking behaviour among men in 16 European countries // Eur. Urol.— 2005. — Vol. 4, № 3 (Suppl.). — P. 60.
  14. Lesch K.P., Merschdorf U. Impulsivity, aggression, and serotonin: a molecular psychobiological perspective // Behav. Sci. Law. — 2000. —Vol. 18. — P. 581—604.
  15. Milsom I., Stewart W., Thüroff J. The prevalence of overactive bladder // Am. J. Manag. Care. — 2000. — Vol. 6 (Suppl. 11). — Р. 565—573.
  16. Ohtake A., Ukai M., Hatanaka T. et al. In vitro and in vivo tissue selectivity profile of Solifenacin succinate (YM905) for urinary bladder over salivary gland in rats // Eur. J. Pharmacol. — 2004. — Vol. 492. — P. 243—250.
  17. Samuels T.A., Mitcheson H.D., Vardy M.D. et al. Solifenacin significantly improves overactive bladder symptoms, symptom-associated bother and other patient-related outcomes: Results from VIBRANT, a double-blind, placebo-controlled trial // EAU annual meeting. — 2009. — Abstr. 190.
  18. Sellers D.J., McKay N. Фармакотерапия гиперактивности мочевого пузыря // Международный реферат. журн.: Урология. — 2009. — № 1.
  19. Solvatore S., Soligo M., Proietti F. et al. Overactive bladder syndrome: considerations in pharmacotherapy and new perspectives // Eur. J. Obstet. Gynecol. Reprod. Biol. — 2005. — Vol. 120. — P. 129—133.
  20. Steers W. Overactive bladder (OAB): What we thought we knew and what we know today // Urol. — 2002. (Suppl. 1). — P. 3—10.
  21. Stewart W., Herzog R., Wein A.J. et al. Prevalence and impact of overactive bladder in the US: Results from the NOBLE program // Neurol. Urodyn. — 2001. — Vol. 20. — P. 403—422.
  22. Toglia M., Andoh M., Hussain I. Solifenacin improves urgency symptoms as assessed by voiding diaries and patient-reported outcomes (PRO) in patients with overactive bladder // International Continence Society annual meeting. — 2006. — Abstr. 155.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2011
##common.cookie##